Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,661 GBX | +0.68% | -0.85% | +14.52% |
Mar. 18 | Health Care Up as Traders Await Policy Statement -- Health Care Roundup | DJ |
Mar. 18 | GSK's Jemperli Combination Shows Potential in Endometrial Cancer Trial | MT |
Sales 2024 * | 31.56B 40.16B | Sales 2025 * | 33.49B 42.62B | Capitalization | 67.4B 85.77B |
---|---|---|---|---|---|
Net income 2024 * | 5.61B 7.13B | Net income 2025 * | 6.25B 7.95B | EV / Sales 2024 * | 2.53 x |
Net Debt 2024 * | 12.57B 16B | Net Debt 2025 * | 9.37B 11.92B | EV / Sales 2025 * | 2.29 x |
P/E ratio 2024 * |
12.1
x | P/E ratio 2025 * |
10.7
x | Employees | 70,212 |
Yield 2024 * |
3.68% | Yield 2025 * |
3.97% | Free-Float | 92% |
Latest transcript on GSK plc
1 day | +0.68% | ||
1 week | -0.73% | ||
Current month | -0.23% | ||
1 month | -0.93% | ||
3 months | +17.02% | ||
6 months | +10.02% | ||
Current year | +14.52% |
Managers | Title | Age | Since |
---|---|---|---|
Emma Walmsley
CEO | Chief Executive Officer | 55 | 10-04-30 |
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
James Ford
CMP | Compliance Officer | - | 95-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
Jonathan Symonds
CHM | Chairman | 66 | 19-08-31 |
Urs Rohner
BRD | Director/Board Member | 65 | 14-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.17% | 11 M€ | +0.83% | - | |
3.15% | 18 M€ | +4.89% | - | |
2.51% | 4 M€ | +9.67% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-18 | 1,661 | +0.68% | 8,969,672 |
24-03-15 | 1,650 | -2.26% | 19,016,980 |
24-03-14 | 1,688 | -0.44% | 5,252,450 |
24-03-13 | 1,695 | +0.59% | 9,359,088 |
24-03-12 | 1,685 | +0.61% | 4,862,779 |
Delayed Quote London S.E., March 18, 2024 at 12:35 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.52% | 85.26B | |
+30.83% | 679B | |
+30.96% | 589B | |
+0.01% | 381B | |
+15.18% | 314B | |
+11.39% | 308B | |
+0.78% | 212B | |
-6.09% | 210B | |
-2.92% | 203B | |
-3.72% | 158B |